We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+26.99%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$12.5B
AUM Growth
+$844M
Cap. Flow
-$1.62B
Cap. Flow %
-12.95%
Top 10 Hldgs %
33.14%
Holding
137
New
32
Increased
25
Reduced
37
Closed
18

Top Buys

Rank Stock Value
1
TMUS icon
T-Mobile US
TMUS
+$331M
2
AON icon
Aon
AON
+$321M
3
WUBA
58.com Inc
WUBA
+$256M
4
BMY icon
Bristol-Myers Squibb
BMY
+$217M
5
TIF
Tiffany & Co.
TIF
+$191M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$1.65B
2
CI icon
Cigna
CI
+$142M
3
FIS icon
Fidelity National Information Services
FIS
+$135M
4
GD icon
General Dynamics
GD
+$132M
5
WAB icon
Wabtec
WAB
+$113M

Sector Composition

Rank Sector Weight
1 Healthcare 43.19%
2 Communication Services 20.54%
3 Technology 10.42%
4 Financials 7.52%
5 Consumer Discretionary 4.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
101
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$3.83M 0.03%
+750,000
New +$3.12M
DMTK
102
DELISTED
DermTech, Inc. Common Stock
DMTK
$2.58M 0.02%
194,675
-410,580
-68% -$5.35M
BRMK.WS
103
DELISTED
Broadmark Realty Capital Inc. Warrants, each exercisable for one fourth (1/4th) share of Common Stock at an exercise price of $2.875 per quarter share
BRMK.WS
$2.28M 0.02%
7,174,613
– –
RNAM
104
DELISTED
Avidity Biosciences
RNAM
$1.41M 0.01%
+50,000
New +$1.44M
GOSS icon
105
Gossamer Bio
GOSS
$75.6M
$1.3M 0.01%
100,000
– –
CTMX icon
106
CytomX Therapeutics
CTMX
$715M
$1.24M 0.01%
+148,952
New +$1.38M
GOL
107
DELISTED
Gol Linhas Aéreas Inteligentes S.A. American Depositary Shares (Each representing Ten Preferred Shares)
GOL
$582K ﹤0.01%
85,838
– –
ATRA icon
108
Atara Biotherapeutics
ATRA
$97.4M
– –
-60,000
Closed -$12.8M
BEAM icon
109
Beam Therapeutics
BEAM
$3.07B
– –
-170,164
Closed -$3.06M
OPTN
110
DELISTED
OptiNose
OPTN
– –
-52,032
Closed -$3.5M
RVMD icon
111
Revolution Medicines
RVMD
$44.9B
– –
-20,733
Closed -$454K
SPY icon
112
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$809B
– –
-2,616,500
Closed -$722M
VSTM icon
113
Verastem
VSTM
$624M
– –
-310,078
Closed -$9.82M
XRX icon
114
Xerox
XRX
$381M
– –
-130,000
Closed -$2.46M
EIGR
115
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-1,670
Closed -$341K
AGTC
116
DELISTED
Applied Genetic Technologies Corporation
AGTC
– –
-586,497
Closed -$1.92M
PHAS
117
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
– –
-84,502
Closed -$280K
QTNT
118
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-62,500
Closed -$9.88M
ADSW
119
DELISTED
Advanced Disposal Services Inc
ADSW
– –
-176,610
Closed -$5.79M
MNTA
120
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-842,683
Closed -$22.9M
PGNX
121
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-8,250,000
Closed -$31.4M
STML
122
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-2,350,000
Closed -$11.4M
AGN
123
DELISTED
Allergan plc
AGN
– –
-9,300,000
Closed -$1.65B
FTSV
124
DELISTED
Forty Seven, Inc. Common Stock
FTSV
– –
-1,105,000
Closed -$105M
RARX
125
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-1,440,000
Closed -$69.1M
1 2 3 4
5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q2 2020 Portfolio in Review

As of Q2 2020, Thomas Steyer held 137 positions worth $12.5B, up 7.2% from $11.7B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Thomas Steyer withdrew a net $1.62B in Q2 2020, closing 18 positions and reducing 37 holdings. Its most notable exit was Allergan plc, an estimated $1.65B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 52% a quarter earlier, followed by Communication Services and Technology.

Against the trend, Thomas Steyer opened a new position in T-Mobile US worth $360M.

  • Thomas Steyer's largest Q2 2020 buy was T-Mobile US: 3,457,631 shares worth $360M.
  • Thomas Steyer added most to Blackstone in Q2 2020, an estimated $125M increase.
  • Thomas Steyer's biggest Q2 2020 reduction was Cigna, cutting an estimated $142M.
  • Thomas Steyer fully exited Allergan plc in Q2 2020, selling an estimated $1.65B.
  • Thomas Steyer's ten largest holdings make up 33% of its $12.5B portfolio in Q2 2020.
  • Thomas Steyer opened 32 new positions and closed 18 in Q2 2020.
  • Thomas Steyer's portfolio value rose 7.2% quarter-over-quarter to $12.5B.

Based on Farallon Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.